Erythropoietin reduces the expression of myostatin in mdx dystrophic mice by D. Feder, M. Rugollini, A. Santomauro Jr, L.P. Oliveira, V.P. Lioi, R. dos Santos, L.G. Ferreira, M.T. Nunes, M.H. Carvalho, P.O. Delgado, A.A.S. Carvalho, F.L.A. Fonseca

Subjects: Get full text

Resistance to recombinant human erythropoietin therapy in haemodialysis patients by Elísio Costa, Margarida Lima, Susana Rocha, Petronila Rocha-Pereira, Flávio Reis, Elisabeth Castro, Frederico Teixeira, Vasco Miranda, Maria do Sameiro Faria, Alfredo Loureiro, Alexandre Quintanilha, Luís Belo, Alice Santos-Silva

Subjects: “…Resistance to recombinant human erythropoietin…”
Get full text

APPLICATION OF ERYTHROPOIETIN THETA IN THERAPY OF ANEMIA IN ONCOLOGIC PATIENTS by O. A. GLADKOV, A. V. SNEGOVOY

Subjects: Get full text

Targeting the transferrin receptor to develop erythropoietin for Alzheimer's disease by Rachita K Sumbria

Get full text

The Effects of Erythropoietin on Learning and Memory in Rats with Alzheimer’s Disease by Parham Reisi, Zohreh Arabpoor, Molood Shabrang, Bahman Rashidi, Hojjatallah Alaei, Mohammad Reza Sharifi, Mahmood Salami, Gholamali Hamidi

Subjects: Get full text

Erythropoietin Levels in Elderly Patients with Anemia of Unknown Etiology. by Zachary Gowanlock, Swetha Sriram, Alison Martin, Anargyros Xenocostas, Alejandro Lazo-Langner

“…METHODS:This study includes all anemic patients over 60 years old who had erythropoietin measured between 2005 and 2013 at a single center. …”
Get full text

Post transplantation anemia: Re-emphasizing the use of erythropoietin by Wael Latif Jabur

Get full text

Serum Erythropoietin Level in Type II Diabetic Nephropathy by Zainab Abbas Jwad, Haider Kamel Zaidan, Mahmoud Hussein Hadwan

“…Results: Serum erythropoietin concentrations were decreased significantly in patients with T2DM compared to that of healthy control subjects. …”
Get full text

Obesity may be erythropoietin dose-saving in hemodialysis patients by Ghada M. El-Kannishy, Abir F. Megahed, Mona M. Tawfik, Ghada El-Said, Rabab T. Zakaria, Nahed A. Mohamed, Eman M. Taha, Alzhraa A. Ammar, Abeer M. Abd Eltawab, Nagy A. Sayed-Ahmed

“…Clinical and laboratory data as well as average doses of ESAs and parenteral iron were recorded. The erythropoietin resistance index (ERI) was calculated. …”
Get full text

Erythropoietin as candidate for supportive treatment of severe COVID-19 by Hannelore Ehrenreich, Karin Weissenborn, Martin Begemann, Markus Busch, Eduard Vieta, Kamilla W. Miskowiak

Subjects: “…SARS-CoV-2; recombinant human erythropoietin…”
Get full text

Differentiation of endogenous erythropoietin and exogenous ESAs by Western blotting by Yukiko Yasuoka, Takashi Fukuyama, Yuichiro Izumi, Tetsuro Yamashita, Yushi Nakayama, Hideki Inoue, Kengo Yanagita, Tomomi Oshima, Taiga Yamazaki, Takayuki Uematsu, Noritada Kobayashi, Yoshitaka Shimada, Yasushi Nagaba, Masashi Mukoyama, Yuichi Sato, Jeff M. Sands, Katsumasa Kawahara, Hiroshi Nonoguchi

“…We developed a new Western blotting method to detect and distinguish endogenous erythropoietin (Epo, 35-38 kDa) and exogenous ESAs (epoetin α and β, 38-42 kDa; darbepoetin α, 47-50 kDa; epoetin β pegol, 93-110 kDa). …”
Get full text

Role of Erythropoietin in Adherence to Antiviral Treatment in Hepatitis C by Rizwan Ahmed

Subjects: Get full text

The effects of erythropoietin on the penicillin induced epileptiform activity in rats by BULUR Ş, DEMİR Ş, BAHADIR A, ANKARALI S, ÖZMERDİVENLİ R, BEYAZÇİÇEK E

Get full text

Erythropoietin as a possible neuroprotective agent in patients with schizophrenia by George E. Barreto

Subjects: Get full text

Serum erythropoietin in acute ischemic stroke: preliminary findings by Lisda Amalia, Gilang Nispu Saputra

“…Abstract Ischemic stroke is the most common stroke, caused by occlusion of cerebral vessels and leading causes of disability. Erythropoietin (EPO) has non-hematopoietic effects as a neuroprotectant after ischemic event. …”
Get full text

Modified recombinant human erythropoietin with potentially reduced immunogenicity by Susantad, Thanutsorn, Fuangthong, Mayuree, Tharakaraman, Kannan, Tit-oon, Phanthakarn, Ruchirawat, Mathuros, Sasisekharan, Ram

“…Recombinant human erythropoietin (rHuEPO) is a biopharmaceutical drug given to patients who have a low hemoglobin related to chronic kidney disease, cancer or anemia. …”
Get full text

Modified recombinant human erythropoietin with potentially reduced immunogenicity by Susantad, Thanutsorn, Fuangthong, Mayuree, Tharakaraman, Kannan, Tit-oon, Phanthakarn, Ruchirawat, Mathuros, Sasisekharan, Ram

“…Recombinant human erythropoietin (rHuEPO) is a biopharmaceutical drug given to patients who have a low hemoglobin related to chronic kidney disease, cancer or anemia. …”
Get full text

Early dosing practices and effectiveness of recombinant human erythropoietin. by Powe, N, Griffiths, R, Greer, J, Watson, A, Anderson, G, de Lissovoy, G, Herbert, R, Eggers, P, Milam, R, Whelton, P

“…In a national longitudinal-cohort study of 59,462 end-stage renal disease (ESRD) patients, we examined dosing and effectiveness of erythropoietin (EPO) during the first year of its use in clinical practice (July 1989 through June 1990). …”

A review of the first year of Medicare coverage of erythropoietin. by Griffiths, R, Powe, N, Greer, J, de Lissovoy, G, Anderson, G, Whelton, P, Watson, A, Eggers, P

“…Recombinant human erythropoietin (rHuEPO) is a new drug for treating anemia associated with end stage renal disease (ESRD). …”

Erythropoietin and neuro-protection in African children with cerebral malaria by Idro, R, Casals-Pascual, C, Gicheru, N, Gwer, S, Roberts, D, Newton, C